<DOC>
	<DOCNO>NCT00062231</DOCNO>
	<brief_summary>RATIONALE : Antibiotics amoxicillin , ciprofloxacin , moxifloxacin may effective prevent control fever neutropenia patient cancer . It yet know whether moxifloxacin alone effective amoxicillin combine ciprofloxacin treat neutropenia fever . PURPOSE : This randomized clinical trial study well moxifloxacin work compare ciprofloxacin together amoxicillin treat neutropenia fever patient cancer .</brief_summary>
	<brief_title>Moxifloxacin Compared With Ciprofloxacin/Amoxicillin Treating Fever Neutropenia Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare rate successful response moxifloxacin v ciprofloxacin combination amoxicillin-clavulanate potassium low-risk febrile neutropenic patient cancer . - Compare time discharge , time discontinuation antimicrobial therapy , time defervescence patient treat regimen . - Compare 28-day survival patient treat regimen . - Determine proportion patient eligible oral therapy therapeutic management include intention early discharge . - Determine medical nonmedical reason continue in-hospital observation care readmission patient . - Determine accuracy physician 's estimate neutropenia duration evaluate predictive value patient . - Validate Multinational Association Supportive Care Cancer low-risk prediction rule predict absence serious medical complication set oral therapy in- outpatient . OUTLINE : This double-blind , randomize , multicenter study . Patients stratify accord institution , underlie disease ( hematologic malignancy v ) , pretreatment single dose ( yes v ) , outpatient status fever onset ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral moxifloxacin daily . Patients also receive oral ciprofloxacin placebo oral amoxicillin-clavulanate potassium placebo twice daily . - Arm II : Patients receive oral ciprofloxacin oral amoxicillin-clavulanate potassium twice daily . Patients also receive oral moxifloxacin placebo daily . Patients fever classify related infection ( i.e. , doubtful ) stop antibiotic therapy day 3 . All patient receive antibiotic complete resolution infection , failure determine anticipate , 28 day . Patients follow 7-10 day . PROJECTED ACCRUAL : A total 530 patient ( 265 patient per treatment arm ) accrue study within approximately 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer develop febrile neutropenia Neutropenia define absolute granulocyte count less 1,000/mm^3 , expect fall le 500/mm^3 within 24 hour , secondary administration chemotherapy and/or radiotherapy within past 30 day Fever define oral temperature great 38.5ºC , 38°C great 2 occasion least 1 hour apart 12hour period , suspect due infection Expected low risk serious medical complication predict Multinational Association Supportive Care Cancer riskindex score great 20 No obvious sign exitsite tunnel intravascular catheter infection No known suspect CNS infection No know highly suspected bacterial , viral , fungal infection PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy No high probability death within 48 hour study enrollment ( i.e. , patient moribund comatose reason little hope recovery OR patient danger , hepatic stupor coma ) Hematopoietic See Disease Characteristics No sign symptom uncontrolled bleed Hepatic Bilirubin great 3 time upper limit normal ( ULN ) Alkaline phosphatase great 3 time ULN AST ALT great 5 time ULN No severe hepatic dysfunction Renal Creatinine great 3.4 mg/dL Creatinine clearance least 25 mL/min No renal failure require hemodialysis peritoneal dialysis Cardiovascular No prior symptomatic arrhythmia No clinically relevant bradycardia No QTc interval prolongation No uncorrected hypokalemia No sign symptom hypotension ( systolic less 90 mm Hg ) Pulmonary No sign symptoms respiratory insufficiency Other Not pregnant nursing Fertile patient must use effective contraception Able swallow oral medication No contraindication oral drug intake No condition likely severely impair drug absorption No prior immediate accelerate reaction penicillin , cephalosporin , fluoroquinolone antibiotic No know allergy hypersensitivity antibiotic study quinolones No sign symptom severe dehydration No sign symptom shock No sign symptom presentation would necessitate IV supportive therapy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy See Disease Characteristics Surgery Not specify Other More 4 day since prior antibacterial agent except follow : A single ( oral parenteral therapeutic ) dose initial diagnosic workup within last 8 hour Lowdose cotrimoxazole ( i.e. , 480 mg daily 960 mg 3 time per week ) prophylaxis Pneumocystis carinii pneumonia More 30 day since prior investigational drug No prior randomization study No concurrent antimicrobial agent No class IA class III antiarrhythmic drug concurrent drug prolong QTc interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>infection</keyword>
	<keyword>neutropenia</keyword>
	<keyword>fever , sweat , hot flash</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>